Evidence map›Paper›PMID 40241724›Full record

ArticleMolecular therapy. Oncology2025

Phosphoribosyl transferase domain containing 1: A prognostic biomarker in testicular germ cell tumors.

Peisheng Huang, Yihao Chen, Yongcheng Shi, Chuanfan Zhong, Huawei Lin, Xiaoxue Yu, Kai Chen, Zhuoya Huang, Le Zhang, Shumin Fang and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular therapy. Oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Peisheng HuangThe First Clinical Medical College, Guangdong Medical University, Zhanjiang, Guangdong 524023, China.
Yihao ChenThe First Clinical Medical College, Guangdong Medical University, Zhanjiang, Guangdong 524023, China.
Yongcheng ShiThe First Clinical Medical College, Guangdong Medical University, Zhanjiang, Guangdong 524023, China.
Chuanfan ZhongDepartment of Urology, Zhujiang Hospital, Southern Medical University, Guangzhou, Guangdong 510282, China.
Huawei LinThe Second Clinical College of Guangzhou Medical University, Guangzhou, Guangdong 510180, China.
Xiaoxue YuThe Second Clinical College of Guangzhou Medical University, Guangzhou, Guangdong 510180, China.
Kai ChenDepartment of Pathology, Guangzhou Medical University Affiliated Women and Children's Medical Center, Guangzhou 510623, China.
Zhuoya HuangDepartment of Pathology, Huizhou Central People's Hospital, No. 41, Eling North Road, Huizhou, Guangdong 516001, China.
Le ZhangInstitute for Integrative Genome Biology, University of California, Riverside, CA 92507, USA.
Shumin FangScience Research Center, Huizhou Central People's Hospital, Huizhou, Guangdong 516001, China.
Jianming LuDepartment of Andrology, Guangzhou First People's Hospital, Guangzhou Medical University, Guangzhou 510180, China.
Jiahong ChenThe First Clinical Medical College, Guangdong Medical University, Zhanjiang, Guangdong 524023, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Due to the heterogeneity and complex classification of testicular germ cell tumors (TGCTs), prognostic evaluation and therapeutic targets remain unclear. Therefore, identifying a novel biomarker to comprehensively assess TGCT prognosis and immunotherapy response is crucial. We collected data from 457 TGCT patient samples and 12 normal testicular samples across six cohorts. Differential expression analysis combined with univariate Cox regression identified prognostic markers for TGCT. Multivariate Cox regression and survival analysis further evaluated the prognostic value of phosphoribosyl transferase domain containing 1 (PRTFDC1). Immunohistochemistry on tissue microarrays validated PRTFDC1's predictive value in clinical samples. We then investigated the relationship between PRTFDC1 and somatic mutations, copy number variations, immune cell infiltration, and immunotherapy response. Through these analyses, we identified PRTFDC1 as an independent risk factor indicating poor prognosis in TGCT. Immunohistochemistry demonstrated high PRTFDC1 expression in TGCT tissues. Gene set enrichment analysis revealed that PRTFDC1 suppresses immune-related pathways. Immune infiltration showed that high PRTFDC1 expression is associated with low CD8

Indexed as

biomarkerimmunotherapyMT: Regular IssueprognosisPRTFDC1testicular germ cell tumor

Identifiers

PMID40241724
PMCPMC12001118

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.